Incremental Predictive Value and Representation of Transcriptomic Features for Immunotherapy Response in Advanced Urothelial Carcinoma
Transcriptomic profiling may improve immunotherapy response prediction, but its incremental value beyond established clinical and tumor biomarkers is unclear. In 298 patients with advanced urothelial carcinoma from IMvigor210, an atezolizumab (PD-L1 inhibitor) trial, we compared knowledge-guided tumor microenvironment...